196 related articles for article (PubMed ID: 1676930)
1. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
[TBL] [Abstract][Full Text] [Related]
2. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
Somerville JE; Clarke LA; Biggart JD
J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Lodato RF; Maguire HC; Greene MI; Weiner DB; LiVolsi VA
Mod Pathol; 1990 Jul; 3(4):449-54. PubMed ID: 2170971
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
[TBL] [Abstract][Full Text] [Related]
6. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
7. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
8. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
11. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
12. Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases.
Sneige N; Wang J; Baker BA; Krishnamurthy S; Middleton LP
Mod Pathol; 2002 Oct; 15(10):1044-50. PubMed ID: 12379750
[TBL] [Abstract][Full Text] [Related]
13. An immunohistochemical study of the c-erbB-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.
Satoh K; Sasano H; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Kobayashi N; Okano T; Toyota T; Sawai T
Cancer; 1993 Jul; 72(1):51-6. PubMed ID: 8099533
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
15. c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study.
Soomro S; Taylor P; Shepard HM; Feldmann M; Sinnett HD; Shousha S
Int J Cancer; 1993 Aug; 55(1):63-5. PubMed ID: 8102130
[TBL] [Abstract][Full Text] [Related]
16. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO
Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
Walker RA; Dearing SJ; Lane DP; Varley JM
J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
[TBL] [Abstract][Full Text] [Related]
18. c-erbB-2 expression in different histological types of invasive breast carcinoma.
Soomro S; Shousha S; Taylor P; Shepard HM; Feldmann M
J Clin Pathol; 1991 Mar; 44(3):211-4. PubMed ID: 1672872
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
Bartkova J; Barnes DM; Millis RR; Gullick WJ
Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II: Epitheliosis and ductal carcinoma in situ.
Böcker W; Bier B; Freytag G; Brömmelkamp B; Jarasch ED; Edel G; Dockhorn-Dworniczak B; Schmid KW
Virchows Arch A Pathol Anat Histopathol; 1992; 421(4):323-30. PubMed ID: 1384227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
